Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Rating of “Strong Buy” by Analysts

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has received a consensus rating of “Strong Buy” from the six research firms that are currently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a buy recommendation and three have given a strong buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $34.00.

A number of research analysts have weighed in on the stock. Citigroup boosted their target price on shares of Catalyst Pharmaceuticals from $33.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, March 3rd. Zacks Research upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 3rd. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a report on Monday, December 29th. Finally, Truist Financial upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Deerfield Management Company L.P. increased its holdings in Catalyst Pharmaceuticals by 72.8% in the 3rd quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock worth $98,003,000 after acquiring an additional 2,095,291 shares during the last quarter. American Century Companies Inc. lifted its holdings in Catalyst Pharmaceuticals by 233.9% during the second quarter. American Century Companies Inc. now owns 1,757,988 shares of the biopharmaceutical company’s stock valued at $38,148,000 after purchasing an additional 1,231,419 shares during the last quarter. Janus Henderson Group PLC boosted its position in Catalyst Pharmaceuticals by 200.6% during the fourth quarter. Janus Henderson Group PLC now owns 1,719,767 shares of the biopharmaceutical company’s stock worth $40,124,000 after purchasing an additional 1,147,565 shares during the period. Morgan Stanley boosted its position in Catalyst Pharmaceuticals by 59.1% during the fourth quarter. Morgan Stanley now owns 2,933,399 shares of the biopharmaceutical company’s stock worth $68,466,000 after purchasing an additional 1,089,775 shares during the period. Finally, Fundsmith LLP increased its stake in shares of Catalyst Pharmaceuticals by 24.2% in the third quarter. Fundsmith LLP now owns 3,363,807 shares of the biopharmaceutical company’s stock worth $66,267,000 after purchasing an additional 654,721 shares in the last quarter. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

CPRX opened at $24.25 on Friday. The firm has a market cap of $2.96 billion, a P/E ratio of 14.35, a PEG ratio of 0.72 and a beta of 0.75. The firm has a 50-day moving average of $24.00 and a 200 day moving average of $22.65. Catalyst Pharmaceuticals has a fifty-two week low of $19.05 and a fifty-two week high of $26.58.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).